@article{aa7414d8497e47dab95b813169aa1462,
title = "Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial",
abstract = "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.",
keywords = "medulloblastoma, phase II trial, temozolomide, medulloblastoma, phase II trial, temozolomide",
author = "Antonio Ruggiero and Cesare Colosimo and Giuseppe Barone and Vita Ridola and Riccardo Riccardi and Graziella Cefalo and Maura Massimino and Filippo Spreafico and Paolo Potepan and Abate, {Massimo E.} and Maurizio Mascarin and Garr{\`e}, {Maria Luisa} and Giorgio Perilongo and Enrico Madon",
year = "2014",
doi = "10.1093/neuonc/not320",
language = "English",
volume = "16",
pages = "748--753",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Carden Jennings Pub.",
}